ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal ...

In recent days, Regeneron Pharmaceuticals announced detailed positive Phase 2 trial results for two novel factor XI ...

Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, ...

Regeneron’s third quarter results were well received by the market, reflecting strong execution in its commercial portfolio and key products. Management attributed the positive momentum to ...

After spending much of the year sloping steadily downward from a January peak, TV drug ad spending picked up in a major way ...

Connect Biopharma Holdings Limited ( CNTB) Discusses Development Strategy for Next-Generation Biologic Targeting Acute and Chronic Respiratory Diseases November 3, 2025 4:15 PM EST ...

Q3 2025 Earnings Call Transcript November 4, 2025 Rhythm Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS ...

Q3 2025 Earnings Call Transcript November 4, 2025 Corvus Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.12, expectations were $-0.14. Operator: Good afternoon, everyone. Thank ...

Regeneron and Sanofi’s Dupixent trial shows major improvement in allergic fungal rhinosinusitis symptoms in patients 6+. Read ...

The contents of this page reflect the allegations in the lawsuits. Cutaneous T-cell lymphoma (CTCL) is a rare and aggressive form of cancer that has been linked to the drug Dupixent in some cases.

When you start a medication like Dupixent (dupilumab), you expect relief from eczema or asthma, not the devastation of a cancer diagnosis. Yet ...